Remdesivir & Obeldesivir: Activity Against Omicron Subvariants (2023-2025)
- Remdesivir and its oral prodrug, obeldesivir, continue to demonstrate potent antiviral activity against recent Omicron subvariants of SARS-CoV-2, according to research published in January 11, 2026, in Open...
- The findings, from a team at Gilead Sciences, Inc., and Johns Hopkins Bloomberg School of Public Health, are reassuring as the virus continues to evolve.
- Remdesivir, an intravenous nucleotide analog prodrug, has been approved for the treatment of COVID-19 in both hospitalized and non-hospitalized patients.
Remdesivir and its oral prodrug, obeldesivir, continue to demonstrate potent antiviral activity against recent Omicron subvariants of SARS-CoV-2, according to research published in , in Open Forum Infectious Diseases and previously in Viruses on .
The findings, from a team at Gilead Sciences, Inc., and Johns Hopkins Bloomberg School of Public Health, are reassuring as the virus continues to evolve. The study assessed the effectiveness of both drugs against Omicron subvariants circulating from through , including XBB.2 and BA.2.86.
Remdesivir, an intravenous nucleotide analog prodrug, has been approved for the treatment of COVID-19 in both hospitalized and non-hospitalized patients. Obeldesivir, an oral formulation, is metabolized into the same active form as remdesivir, offering a potentially more convenient administration route. Both drugs target the viral RNA-dependent RNA polymerase, known as Nsp12, which is crucial for viral replication.
The research involved evaluating the antiviral activity against recent Omicron variants using clinical isolates and through a replicon system, where the variant-defining substitutions were introduced into a replicating RNA molecule. This approach allows scientists to isolate and study the impact of specific mutations on drug susceptibility.
The data indicate that remdesivir and obeldesivir maintain their antiviral potency against these newer Omicron subvariants. While specific details regarding the degree of potency weren’t provided, the consistent activity suggests that the virus hasn’t developed significant resistance to these medications. What we have is particularly important given the ongoing emergence of new variants with potentially altered characteristics.
The study authors, led by Lauren Rodriguez, PhD, of Gilead Sciences, Inc., emphasize the continued relevance of these antiviral treatments in the context of evolving SARS-CoV-2 strains. The consistent activity observed across multiple Omicron subvariants suggests that remdesivir and obeldesivir remain valuable tools in managing COVID-19.
The ongoing monitoring of antiviral effectiveness is critical. As the virus mutates, it’s essential to ensure that existing treatments remain effective. This research provides valuable data supporting the continued use of remdesivir and obeldesivir, but continued surveillance and research are necessary to address future viral evolution.
The findings are consistent with earlier research evaluating the activity of remdesivir against previous Omicron subvariants, including BA.1 to XBF. This body of evidence reinforces the understanding that remdesivir and obeldesivir are relatively robust against the range of variants that have emerged to date.
While these findings are encouraging, it’s important to remember that antiviral treatments are most effective when administered early in the course of infection. Individuals experiencing symptoms of COVID-19 should consult with their healthcare provider to determine the appropriate course of treatment, which may include antiviral medications, supportive care, and other interventions.
Further research is ongoing to investigate the potential for combination therapies and to develop new antiviral agents that can target different aspects of the viral lifecycle. The goal is to build a comprehensive arsenal of tools to combat COVID-19 and to prepare for future pandemic threats.